Latest Breaking News On - Serious adverse events - Page 4 : comparemela.com

Neuraptive Therapeutics, Inc Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves

The NEUROFUSE Study is an ongoing 48-week Multicenter, Randomized, evaluator-blinded, Phase 2a study in upper extremity nerve transections comparing NTX-001…

United statesNeuraptive therapeutics incEvaluator blinded studyTreatment emergent adverse eventsSerious adverse eventsMichigan hand questionnaireNumeric pain rating scaleSemmes weinstein monofilament testPatient global impressionWeek resultsTotal scoreSecondary endpoints

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South africaMark emalfarbJulian naidooUniversity of the witwatersrandRubic one healthDyadic international incWits health consortiumAfrican health products regulatory authorityDyadic internationalSecurities exchangeSerious adverse eventsClinical study reportClinical trial applicationChief executive officerOne healthSecurities act

Dyadic International, Inc (DYAI) Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Dyadic International, Inc (DYAI) Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South africaJulian naidooMark emalfarbAfrican health products regulatory authorityDyadic international incRubic one healthDyadic internationalClinical trial applicationSerious adverse eventsChief executive officer

Alpha Tau (DRTS) Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Alpha Tau (DRTS) Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Corey millerAlpha daAlpha tau medical ltdTherapeutic endoscopy of the division gastroenterologyLady davis instituteMcgill universityProfessor of medicine at mcgill universityInstitute transmedtechMcgill centre for translational research in cancerAlpha tau medicalSerious adverse eventsJewish general hospitalPancreatic cancer awarenessTherapeutic endoscopyAssistant professorAssociate researcher

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received.

Israel generalUnited statesAlpha daCorey millerYona keisariItzhak kelsonProfessor of medicine at mcgill universityMcgill universityInstitute transmedtechMcgill centre for translational research in cancerTel aviv universityExchange commissionAlpha tau medical ltdTherapeutic endoscopy of the division gastroenterologyLady davis instituteSerious adverse events